Back to Journals » Biologics: Targets and Therapy » Volume 13

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)

Authors Salehzadeh F, Mohammadikebar Y, Enteshary A, Ghanbarpour O, Mirzarahimi M

Received 31 January 2019

Accepted for publication 11 April 2019

Published 27 May 2019 Volume 2019:13 Pages 97—99

DOI https://doi.org/10.2147/BTT.S203753

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Doris Benbrook


Farhad Salehzadeh,1 Yusef Mohammadikebar,2 Afsaneh Enteshary,2 Omid Ghanbarpour,1 Mehrdad Mirzarahimi1

1Department of Pediatric, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran; 2Department of Internal Medicine, Emam Khomeini Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran

Abstract: We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years’ follow-up.

Keywords: pyoderma gangrenosum, infliximab, childhood

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]